Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-CR-04
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-CR-04 is an investigational mRNA vaccine developed by GSK (GlaxoSmithKline) that encodes the spike (S) glycoprotein of the SARS-CoV-2 Omicron variant. As an mRNA-based therapeutic, it utilizes lipid nanoparticle or similar delivery technology to transport the genetic sequence into host cells, which then translate the mRNA into the viral spike protein. This process triggers an immune response, including the production of neutralizing antibodies and T-cell activation, specifically tailored to the Omicron variant. The vaccine is being evaluated in Phase 1 clinical trials (First Time in Human) to assess its safety, reactogenicity, and immunogenicity in healthy adults, particularly as a booster for individuals previously immunized with other SARS-CoV-2 mRNA vaccines.
- Other names
- GSK Omicron variant S glycoprotein vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA-CR-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-CR-04.